COMPARISON OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED RADIONUCLIDE THERAPY (TRT) WITH LUTETIUM-177 (177LU) VIA ANTIBODY J591 VS SMALL MOLECULE LIGAND PSMA-617

被引：0
|
作者：
Niaz, Muhammad Junaid
Skafida, Myrto
Osborne, Joseph
Nanus, David
Molina, Anna
Thomas, Charlene
Vallabhajosula, Shankar
Christos, Paul
Bander, Neil
Tagawa, Scott
机构：
来源：
JOURNAL OF UROLOGY | 2020年 / 203卷
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PD16-11
引用
收藏
页码：E367 / E367
页数：1
相关论文
共 50 条
  • [1] SAFETY OF LUTETIUM-177 PROSTATE SPECIFIC MEMBRANE ANTIGEN-617 (PSMA-617) RADIOLIGAND THERAPY IN SEVERE RENAL IMPAIRMENT
    Sutherland, Duncan
    INTERNAL MEDICINE JOURNAL, 2023, 53 : 45 - 46
  • [2] Lutetium-177-labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) for metastatic non-prostate solid tumors
    Pail, Orrin
    Kaur, Gurveen
    Dyke, Jonathan
    Jhanwar, Yuliya
    Christos, Paul
    Ocean, Allyson
    Shah, Manish
    Shore, Tsiporah
    Schneider, Bryan
    Scheff, Ronald
    Beltran, Himisha
    Ballon, Douglas
    Robinson, Brian
    Nanus, David M.
    Bander, Neil H.
    Tagawa, Scott T.
    CANCER RESEARCH, 2014, 74 (19)
  • [3] Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies
    Amir Iravani
    John Violet
    Arun Azad
    Michael S. Hofman
    Prostate Cancer and Prostatic Diseases, 2020, 23 : 38 - 52
  • [4] Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies
    Iravani, Amir
    Violet, John
    Azad, Arun
    Hofman, Michael S.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2020, 23 (01) : 38 - 52
  • [5] [177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Seifert, Robert
    Boegemann, Martin
    LANCET ONCOLOGY, 2018, 19 (08): : E371 - E371
  • [6] Phase 2 trial of 177Lutetium (177Lu) radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 (177Lu-J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC).
    Morris, M. J.
    Milowsky, M. I.
    Pandit-Taskar, N.
    Divgi, C.
    David, K. A.
    Rozario, C. P.
    Vallabhajosula, S.
    Goldsmith, S. J.
    Scher, H. I.
    Nanus, D. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 244S - 244S
  • [7] Dosimetry in Lu-177-PSMA-617 prostate-specific membrane antigen targeted radioligand therapy: a systematic review
    Nautiyal, Amit
    Jha, Ashish K.
    Mithun, Sneha
    Rangarajan, Venkatesh
    NUCLEAR MEDICINE COMMUNICATIONS, 2022, 43 (04) : 369 - 377
  • [8] Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review
    Sutherland, Duncan E. K.
    Kashyap, Raghava
    Jackson, Price
    Buteau, James P.
    Murphy, Declan G.
    Kelly, Brian
    Spain, Lavinia
    Sandhu, Shahneen
    Azad, Arun A.
    Medhurst, Elizabeth
    Kong, Grace
    Hofman, Michael S.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [9] Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
    Gadot, Moran
    Davidson, Tima
    Aharon, Margalit
    Atenafu, Eshetu G.
    Malki, Avraham
    Levartovsky, Meital
    Saad, Akram
    Domachevsky, Liran
    Berger, Raanan
    Leibowitz, Raya
    CANCERS, 2020, 12 (05)
  • [10] [177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer reply
    Hofman, Michael S.
    Violet, John
    Hicks, Rodney J.
    Sandhu, Shahneen
    LANCET ONCOLOGY, 2018, 19 (08): : E373 - E373
12345